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ABSTRACT
Background. Because patients with differentiated thyroid
carcinoma (DTC) presenting with distant metastasis (DM)
have a particularly poor prognosis, examining the prog-
nostic factors in this group is essential. We aimed to
evaluate the prognostic factors affecting cancer-specific
survival (CSS) in DTC patients presenting with DM.
Methods. Of the 1227 DTC patients, 51 (4.2 %) presented
with DM at diagnosis. All patients underwent a total thy-
roidectomy, followed by radioiodine (RAI) ablation and
postablation whole body scan (WBS). Patients were con-
sidered to have an osseous metastasis if one of the
metastatic sites involved a bone, while RAI avidity was
determined by any visual uptake in a known metastatic site
on the first WBS. Factors predictive of CSS were deter-
mined by univariate and multivariate analyses by the Cox
proportional hazard model.
Results. In univariate analysis, older age (relative risk
[RR] 1.050, 95 % confidence interval [CI] 1.010–1.091,
P = 0.014), DM discovered before WBS (RR 3.401, 95 %
CI 1.127–10.309, P = 0.030), follicular thyroid carcinoma
(RR 3.095, 95 % CI 1.168–8.205, P = 0.025), osseous
metastasis (RR 4.695, 95 % CI 1.379–15.873, P = 0.013),
non-RAI avidity (RR 3.355, 95 % CI 1.280–8.772,
P = 0.014), and external beam radiotherapy to DM (RR
3.241, 95 % CI 1.093–9.614, P = 0.034) were significant
poor prognostic factors for CSS. In the multivariate anal-
ysis, after adjusting for other factors, osseous metastasis
(RR 6.849, 95 % CI 1.495–31.250, P = 0.013) and non-
RAI avidity (RR 7.752, 95 % CI 2.198–27.027,
P = 0.001) were the two independent poor prognostic
factors for CSS. Older age almost reached statistically
significance (RR 1.055, 95 % CI 0.996–1.117, P = 0.068).
Conclusions. DTC patients presenting with DM accounted
for 4.2 % of all patients. Because osseous metastasis and
RAI avidity were independent prognostic factors, future
therapy should be directed at improving the treatment
efficacy of osseous and/or non-RAI-avid metastases.
Differentiated thyroid carcinoma (DTC) accounts for
over 90 % of all follicular cell–derived thyroid malignan-
cies and comprises two distinct histological types, papillary
thyroid carcinoma and follicular thyroid carcinoma.1
Despite the rising incidence, its prognosis remains excel-
lent, with a 10-year cancer-specific survival (CSS) of up to
90 %.2,3 However, up to 9 % of DTC patients present with
distant metastasis (DM) at the time of diagnosis.4 Unlike
the rest of the group, this specific group carries a far worse
prognosis.2 In fact, this group accounts for much of the
overall cancer-specific deaths.2,3
Although previous studies have identified a number of
prognostic factors significantly associated with poorer
CSS, such as age[45 years, poor differentiation, follicular
thyroid carcinoma, Hu¨rthle cell variant, iodine avidity,
incomplete local control, and extrapulmonary DM, some of
these studies tended to group and analyze those with DM at
diagnosis and those with DM discovered some time after
initial treatment together.4–14 It is recognized both groups
differ in their prognosis and treatment response, and so
they ideally should be considered separately.4,8,11 Fur-
thermore, both the prognostic factors and the outcomes
varied between studies.4,8,9,11 Apart from possible referral
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differences, some studies included patients who were ini-
tially managed outside their primary institution. This may
pose a selection bias because those with more advanced or
extensive disease and/or with poorer response to initial
treatment were more likely referred to a tertiary referral
institution.
To minimize patient heterogeneity, the present study
aimed to select only patients who had surgery, subsequent
radioiodine (RAI), and whole body scan (WBS) at our
institution. We aimed to review our single-institution
experience and to specifically evaluate the prognostic
factors associated with CSS of DTC patients with DM at
diagnosis.
PATIENTS AND METHODS
Patients
The present study protocol was approved by the local
institutional review board. From 1986 to 2010, a total of
1227 patients underwent surgery for histologically proven
DTC. Of these, 51 patients (4.2 %) were found to have DM
at diagnosis. These were the patients whose DM was
identified any time before surgery or at the time of the first
postablation WBS (i.e., 2–3 months after surgery). Patients
who underwent primary thyroid surgery, RAI, or WBS
performed outside our institution or those who had their
DM discovered after the first WBS were excluded. Also, if
the primary tumor contained a poorly differentiated or
anaplastic component, it was excluded.
Treatment Protocol
Details of the treatment and follow-up protocols have
been described previously.2 Total thyroidectomy was pre-
ferred. Simultaneous central (level VI) with or without
lateral (levels II–V) selective neck dissection was per-
formed for clinically proven cervical lymph node
metastasis. Surgical metastasectomy was considered if the
metastasis was solitary and resectable. Two months after
initial surgery, a standard ablative RAI dose of 3 GBq or
80 mCi was provided after levothyroxine (LT4) withdrawal
or with recombinant thyroid-stimulating hormone (rTSH).
TSH-suppressive LT4 treatment was commenced immedi-
ately afterward. This was followed by the postablation WBS
or posttherapy scan 4–7 days later. The subsequent therapy
for DM usually comprised 5.5 GBq (or 150 mCi) RAI and
was administered periodically every 6 months until no more
uptake was observed on WBS or until disease progressed
despite treatment. External beam radiotherapy (EBRT) to
the neck was provided to patients with extensive extrathy-
roidal tumor extension, incomplete resection, and/or
extracapsular lymph node metastasis (40 Gy over 3 weeks
for adjuvant treatment and 50 Gy over 4 weeks for gross
residual disease). In some cases of incomplete resection or
gross residual tumor after surgery, EBRT might be provided
before RAI because it is more effective in controlling gross
residual disease.15 EBRT to metastatic sites was performed
for symptomatic and unresectable bone or brain lesions,
such as vertebral metastases resulting in neurological or
compressive symptoms that were not amenable to surgery.
All treatment decisions were made after discussion at a
multidisciplinary tumor board meeting. Although the above
protocol was followed, individual patients’ preference and
performance status were considered.
METHODS
All data, including disease status and cause of death,
were prospectively collected after 1995. The diagnosis of
DM was based on clinical and/or positive findings on
WBS, radiography (e.g., chest x-ray), CT scan, MRI, or
tissue biopsy. Iodine avidity was determined by visual
uptake in the known site of metastatic disease by WBS
after the first RAI ablation under hypothyroid conditions.
Absence of visual uptake on WBS was defined as disease
being non-RAI avid. Sites of DM were classified into
pulmonary versus extrapulmonary and into osseous versus
nonosseous. For multiple DM sites, if one of the sites
involved the lung or bone, the patient would still be clas-
sified into pulmonary or osseous, respectively. The latest
disease status was classified into progressive disease, static
disease, or remission on the basis of the serum thyroglob-
ulin (Tg) trend and/or the changes in the size and number
of metastases by diagnostic WBS or axial imaging. Patients
were classified as having died of DTC if this was stated as
the primary cause of death or as a contributing cause of
death in the death certificate. In patients in whom the cause
of death was uncertain, the patient was assumed to have
died from DTC if extensive progressive metastatic disease
was present at the last follow-up.
Tg Measurement
Stimulated Tg (sTg) was defined as a Tg level measured
in the presence of TSH [30 mIU/L either by 4-week LT4
withdrawal or rTSH injections. The preablation sTg level
was assessed just before the RAI ablation, and the postab-
lation sTg was assessed 6 months after RAI ablation. Tg
levels were measured in the same laboratory, although less
sensitive biochemical assays were used before the year
2006.16 After that, the assay used was the Immulite 2000
(Diagnostic Products, Roche, Los Angeles, CA). This was
calibrated against the CRM-457 standard. Normal reference
range was\0.5–55 lg/L, and sensitivity was\0.2 lg/L.
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Statistical Analysis
Statistical analysis was performed by Chi-square or
Fisher’s exact test to compare categorical variables, and the
Mann–Whitney U-test was used to compare continuous
variables between groups. Continuous variables were
expressed as medians with ranges. Survival was calculated
from the diagnosis of DM to the date of last follow-up or
death. CSS was calculated by the Kaplan–Meier method,
and survival outcomes were compared by the log rank test.
Factors predictive of CSS were determined by univariate
and multivariate analyses by the Cox proportional hazard
model. All statistical analyses were performed by SPSS
software, version 18.0 (SPSS, Chicago, IL).
RESULTS
Table 1 shows the baseline characteristics of the cohort.
DM was identified before the first postablation WBS in 38
patients (74.5 %) and by first postablation WBS in 13
patients (25.5 %). Of the 38 patients diagnosed before
WBS, 20 were asymptomatic, while the other 18 had
symptoms/signs as a result of the DM. These symptoms/
signs included bilateral lower limb weakness (n = 3), neck
skin nodules (n = 2), respiratory complaints (n = 3), rib
pain (n = 1), back pain (n = 1), generalized bone pain
(n = 2), long bone fracture (n = 1), pelvic mass (n = 1),
scalp mass (n = 2), seizure (n = 1), and sternal swelling
(n = 1). Of the 20 asymptomatic patients, 15 patients had
visible lung masses on plain preoperative chest x-ray, while
the other 5 patients had bone and/or lung metastases
detected on preoperative CT scan.
Ten patients (19.6 %) underwent surgical metastasec-
tomy. Three patients had metastases removed before initial
thyroid surgery: one underwent a craniotomy for a solitary
brain metastasis, while the other two underwent excision of
spinal bone metastasis, spinal cord decompression, and
fixation. Four patients had concomitant metastasectomy at
the time of the thyroid surgery: two underwent excision of
neck skin metastases, and two underwent en bloc manub-
rial and clavicular excision for bone and mediastinal
metastases. Three patients required metastasectomy after
the thyroid surgery: one presented with spinal cord com-
pression from a spinal metastasis 10 days after thyroid
surgery and so required excision of the vertebral metasta-
sis, spinal cord decompression, and fixation. The other two
patients underwent excision of skeletal solitary metastasis
involving the paraspinal muscle. Twenty-eight patients
(54.9 %) had single-site DM (lung in 18 patients, bone in 7
patients, brain in 3 patients). The other 23 patients had
more than one metastatic site, including lung and bone
(n = 12), lung and mediastinum (n = 3), lung and brain
(n = 4), lung and skin (n = 2), and lung and scalp (n = 2).
After surgery, all patients received one ablative dose of
3–5.5 GBq RAI. The median cumulative RAI dose was
11.0 (3.0–27.5) GBq. The median cumulative dose was
significantly higher in RAI-avid DM than non-RAI-avid
DM (11.0 vs. 5.5 GBq, P = 0.006). In our cohort, despite
good tumor response (as judged by a combination of
decreasing Tg and radiological response), 4 patients refused
TABLE 1 Baseline characteristics of the 51 patients with differen-
tiated thyroid carcinoma presenting with distant metastasis
Characteristic Valuea
Age at diagnosis of distant metastasis (y) 62.1 (12.2–75.1)
Gender
Male 15 (29.4)
Female 36 (70.6)
Discovery of distant metastasis
At diagnosis of primary tumor 38 (74.5)
Asymptomatic 20 (39.2)
Symptomatic 18 (35.3)
At first postablation whole body scan 13 (25.5)
Type and extent of initial operation
Total thyroidectomy 23 (45.1)
Total thyroidectomy ? CND 2 (3.9)
Total thyroidectomy ? CND
? metastasectomy
3 (5.9)
Total thyroidectomy ? SND 22 (43.1)
Total thyroidectomy ? SND
? metastasectomy
1 (2.0)
Histopathology
Papillary thyroid carcinoma 34 (66.7)
Follicular thyroid carcinoma 17 (33.3)
Primary tumor characteristics
Size (cm) 3.0 (0.5–12.0)
Extrathyroidal extension 26 (51.0)
Tumor multifocality 25 (49.0)
Cervical lymph node metastases (pN1) 32 (62.7)
Postoperative treatment
Radioiodine ablation/therapy 51 (100)
External radiotherapy to neck region 14 (27.5)
Provided before radioiodine 4 (7.8)
Provided after radioiodine 10 (19.6)
External radiotherapy to distant metastasis 22 (43.1)
Preablation stimulated thyroglobulin
(ng/mL)
1478 (2.7 to [ 4800)
Postablation stimulated thyroglobulin
(ng/mL)
788.5 (0.2 to [ 4800)
Need for reoperative neck dissection 7 (13.7)
Time interval from initial operation to neck
reoperation (mo)
59.3 (12.4–63.9)
CND central neck dissection, SND selective neck dissection
a Data are presented as median (range) or n (%)
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further RAI therapy after ablation. Two patients failed to
complete EBRT to DM (one for brain metastasis and one for
bone metastasis). Of the 14 patients who received EBRT, 4
received EBRT before RAI ablation because they were
considered to have gross residual disease left in their thy-
roid bed and so to be at increased risk of locoregional
recurrence. The median follow-up was 100.4 (range
6.6–229.1) months. At the time of analysis, 18 (35.3 %)
died of DTC and 2 (3.9 %) died of an unrelated cause. Of
the 31 patients still alive, 14 had progressive disease, 12 had
static disease, and 5 were in remission. The 5-year and
10-year overall survival were 85.4 % and 52.4 %, respec-
tively, while the 5-year and 10-year CSS were 87.6 % and
58.7 %, respectively.
Table 2 shows the univariate analysis of CSS by the Cox
proportional hazard model. Older age at diagnosis (relative
risk [RR] 1.050, 95 % confidence interval [CI] 1.010–
1.091, P = 0.014), DM discovered at presentation (RR
3.401, 95 % CI 1.127–10.309, P = 0.030), follicular thy-
roid carcinoma (RR 3.095, 95 % CI 1.168–8.205,
P = 0.025), osseous metastasis (RR 4.695, 95 % CI 1.379–
15.873, P = 0.013), non-RAI avidity (RR 3.355, 95 % CI
1.280–8.772, P = 0.014), and EBRT to DM (RR 3.241,
95 % CI 1.093–9.614, P = 0.034) were statistically sig-
nificant poor prognostic factors for CSS.
Table 3 shows the multivariate analysis of CSS by the
Cox proportional hazard model. After adjusting for other
significant factors such as age at diagnosis (P = 0.068),
timing of DM (P = 0.792), histopathology (P = 0.766),
and EBRT to DM (P = 0.413), osseous metastasis (RR
6.849, 95 % CI 1.495–31.250, P = 0.013) and non-RAI
avidity (RR 7.752, 95 % CI 2.198–27.027, P = 0.001)
were independent poor prognostic factors for CSS. Age at
diagnosis almost reached statistical significance (RR 1.055,
95 % CI 0.996–1.117, P = 0.068).
Figure 1 shows the CSS survival curves between those
with osseous metastasis and with nonosseous metastasis.
The 5-year and 10-year CSS between patients with osseous
metastasis and with nonosseous metastasis were 68.6 % and
45.7 % vs. 100 % and 67.6 %, respectively (P = 0.004).
Figure 2 shows the CSS survival curves between those
with RAI-avid DM and with non-RAI-avid DM. The 5-year
and 10-year CSS between patients with RAI-avid DM and
with non-RAI-avid DM were 91.7 % and 67.9 % vs.
77.4 % and 33.2 %, respectively (P = 0.007).
DISCUSSION
This study represented our 25-year single-institution
experience of managing DTC presenting with DM and was
aimed at examining prognostic factors associated with this
cohort. Unlike previous reports, we excluded those who
TABLE 2 Univariate Cox regression analysis of in differentiated
thyroid carcinoma patients presenting with distant metastasis
Variable n (%) Relative risk
(95 % CI)
P
Age at diagnosis of distant
metastasis (y)
51 (100) 1.050 (1.010–
1.091)
0.014*
Sex 0.438
Male 15 (29.4) 1
Female 36 (70.6) 1.543 (0.515–
4.630)
Discovery of distant
metastasis
0.030*
At diagnosis or before
surgery
38 (74.5) 1
At postablation whole body
scan
13 (25.5) 0.294 (0.097–
0.887)
Primary tumor size (cm) 51 (100) 1.126 (0.840–
1.509)
0.470
Histopathology 0.023*
Papillary thyroid carcinoma 34 (66.7) 1
Follicular thyroid carcinoma 17 (33.3) 3.095 (1.168–
8.205)
Extrathyroidal extension 0.150
No 25 (49.0) 1
Yes 26 (51.0) 2.210 (0.751–
6.504)
Tumor multifocality 0.360
No 26 (51.0) 1
Yes 25 (49.0) 1.572 (0.597–
4.142)
Tumor bilaterality 0.799
No 38 (74.5) 1
Yes 13 (25.5) 1.159 (0.371–
3.619)
Cervical lymph node
metastasis
0.166
No 19 (37.3) 1
Yes 32 (62.7) 1.972 (0.754–
5.155)
Completeness of primary
operation
0.956
Complete 39 (76.5) 1
Incomplete 12 (23.5) 1.031 (0.347–
3.068)
Metastasectomy 0.967
No 41 (80.4) 1
Yes 10 (19.6) 1.064 (0.228–
4.673)
Need for neck reoperation 0.483
No 44 (86.3) 1
Yes 7 (13.7) 1.704 (0.384–
17.576)
Stimulated thyroglobulin
(ng/mL)
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developed DM after the first WBS.4–14 This was important
because first, the prognosis of those discovered before or
by WBS is different from those discovered after WBS.4,12
Second, some DM are believed to be a result of locore-
gional disease progression (such as disease progressed
from the central neck to the mediastinum) and so might
represent a different disease altogether.4,8,9,11 Third, those
discovered before or by WBS are often considered more
‘‘RAI naive’’ and so they are generally more RAI respon-
sive and have higher RAI avidity.4,8
Similar to previous studies, our data confirmed that
osseous metastasis and non-RAI-avid DM were indepen-
dent poor prognostic factors for CSS.6,7,9 In one of the
largest series, Durante et al. reported that those with osseous
metastasis had significantly poorer 10-year overall survival
than those with pulmonary metastasis (25 % vs. 63 %,
P \ 0.001).6 Similar observations had been made in other
studies.11–14,17,18 Ideally, our analysis could have been
TABLE 2 continued
Variable n (%) Relative risk
(95 % CI)
P
Before ablation 51 (100.0) 1.000 (0.999–
1.001)
0.373
After ablation 51 (100.0) 1.000 (0.999–
1.001)
0.580
Site of distant metastasis 0.256
Pulmonary 41 (80.4) 1
Extrapulmonary 10 (19.6) 3.241 (0.880–
7.631)
Site of distant metastasis 0.008*
Nonosseous 30 (58.8) 1
Osseous 21 (41.2) 3.788 (1.414–
10.101)
No. of DM sites 0.085
Single 28 (54.9) 1
Two or more 23 (45.1) 2.376 (0.888–
6.358)
Radioiodine aviditya 0.014*
Yes 37 (72.5) 1
No 14 (27.5) 3.355 (1.280–
8.772)
Cumulative radioiodine
activity (GBq)
51 (100) 0.944 (0.859–
1.037)
0.230
EBRT to the neck region 0.665
No 37 (72.5) 1
Yes 14 (27.5) 1.242 (0.465–
3.316)
EBRT to distant metastasis 0.034*
No 29 (56.9) 1
Yes 22 (43.1) 3.241 (1.093–
9.614)
CI confidence interval, DM distant metastasis, EBRT external beam
radiotherapy
a Based on the finding of the first postablation whole body scan
* Statistically significant (P \ 0.05)
TABLE 3 Multivariate analysis for CSS in differentiated thyroid
carcinoma patients presenting with distant metastasis
Covariate b
coefficient
Relative risk
(95 % CI)
p
Age at diagnosis of distant
metastasis (y)
0.053 1.055 (0.996–
1.117)
0.068
Discovery of distant
metastasis
0.792
At diagnosis or before
surgery
1
At postablation whole body
scan
0.234 0.791 (0.139–
4.494)
Histopathology 0.766
Papillary thyroid carcinoma 1
Follicular thyroid carcinoma 0.226 1.255 (0.283–
5.559)
Site of distant metastasis 0.013*
Nonosseous 1
Osseous 1.922 6.849 (1.495–
31.250)
Radioiodine aviditya 0.001*
Yes 1
No 2.044 7.752 (2.198–
27.027)
EBRT to distant metastasis 0.413
No 1
Yes 0.530 1.699 (0.477–
6.050)
CSS cancer-specific survival, CI confidence interval, ERBT external
beam radiotherapy
a Based on the finding of the postablation whole body scan
* Statistically significant (P \ 0.05)
FIG. 1 Cancer-specific survival curves between those with osseous
metastasis (n = 21) and those with nonosseous metastasis (n = 30)
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improved by selecting a group with osseous metastasis only,
but because the number of these patients was so small
(n = 7), it was difficult to do so. One explanation why
osseous metastasis had a poorer survival outcome might be
because RAI is generally less effective for osseous metas-
tasis.5,17,18 In our opinion, adopting an aggressive surgical
approach by resecting solitary osseous metastasis may
improve the prognosis of this group. However, because not
all osseous metastases are amenable to surgical resection,
other systematic treatment options, such as intravenous
bisphosphonates and new targeted drugs, may be important
and should be considered together with RAI and EBRT.17,18
RAI avidity was found to be the other independent
prognostic factor for CSS, a finding consistent with other
studies.4,9,10 The reasons why RAI avidity might have been
a significant prognostic factor are 2-fold. First, non-RAI-
avid DM is generally less differentiated and so behaves
more aggressively.19–21 Second, non-RAI-avid DM are less
responsive to RAI therapy.21 RAI remains the most
effective treatment for DM and could achieve long-lasting
remission in young patients.5,6 In our study, the 5 patients
in remission were relatively young. They were 12.2
to 59.3 years old at diagnosis. Although toward the
latter period some patients with negative WBS did undergo
F-18-fluorodeoxyglucose–positron emission tomography
(FDG-PET) to further delineate their DM, the FDG-PET
data were not available at the time of analysis, and so the
prognostic value of FDG positivity could not be assessed.
Nevertheless, because RAI avidity was a significant factor,
findings on the FDG-PET scan probably carry significant
prognostic value, as there is often a flip-flop phenomenon
between RAI and FDG uptakes.20,22
Although previous studies found age at DM to be a
significant factor, it did not reach statistical significant
(P = 0.068) in our multivariate analysis.8–12,14 Perhaps
with a larger sample size it might become significant. From
our data, 4 patients (30.8 %) aged \45 years eventually
died of DTC, while 14 patients (36.8 %) aged C45 years
died of DTC. Other previously identified significant factors
like incomplete local control or postsurgical sTg level were
not significant in this study.13,14 Perhaps these findings
imply that the treatment priority for DM should be on
distant disease control rather than on local disease control.
Although these findings appeared to be in discordant with
some studies that found a significant correlation between
adequate local control and improved survival outcome,
they were consistent with the recommended treatment
guidelines for metastatic DTC.1,14 One of the main short-
comings of our study was that the number of patients was
relatively small, and so some insignificant findings might
have been related to the inadequate power of the study.
Because we defined RAI avidity as visual uptake in the
known site of metastatic disease by WBS after the first RAI
ablation, we did not fully account for some patients who
might have an initial positive postablation WBS and a
subsequent negative diagnostic WBS, or some patients
with mixed RAI-avid and non-RAI-avid DM.
DTC patients presenting with DM at diagnosis accounted
for 4.5 % of all patients treated at our institution. Patients
with osseous metastasis had a significantly worse CSS than
those with nonosseous metastasis, while patients with non-
RAI-avid metastasis also had a significantly worse CSS
than those with RAI-avid metastasis. Both osseous metas-
tasis and RAI avidity were independent prognostic factors
for CSS in DTC patients presenting with DM. To further
improve the overall prognosis, future therapy should be
directed at improving the efficacy of treatment of patients
with osseous and/or non-RAI-avid metastases.
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